Status: Not yet recruiting
LMT503 First-in-human SAD, MAD, and FE Study
This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.
Participants needed: 72
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Lmito Therapeutics Inc.Updated: Sep 1, 2026Locations: 1
Eligibility criteria
Age : 18 to 65 years, inclusive, at screening [+12]
Previous participation in the current study. [+14]